The Southern California driver who swerved into a large group of 20 joggers in training with the Leukemia & Lymphoma Society was sentenced to over 35 years in prison.
Early in the morning of August 30, 2008, 57 year old Gregory Doan was driving his van with a blood-alcohol level (BAL) of 0.21, well over twice the legal limit (it would later be determined that he also had recently taken opiates) when he swerved into twenty joggers who were taking part in the LLS's Team-in-Training program. 66 year old Carolyn Samuels, a woman who had been running one charity marathon a year since turning 50 years old, died as a resut of her injuries.
Doan's sentence includes a 15 year stretch for gross vehicular manslaughter while intoxicated and hit-and-run, along with 19 counts of assault with a deadly weapon. He pleaded no contest.
He will be eligible for parole in 17 years and will donate the maximum amount of money by law from the wages he earns working in prison—which is half (estimated to amount to around $9 per month)—to the Team-in-Training program.
Source: The Daily Source
Amazon.com is pleased to have the Lymphoma Information Network in the family of Amazon.com associates. We've agreed to ship items...
The question ought to be what are myelodysplastic syndromes (MDS), since this is a group of similar blood and bone marrow diseases that...
Merkel Cell Carcinoma (MCC) is a very rare and aggressive skin cancer that usually develops when a person is in his or her 70s. It is...
At some point, the Seattle biotech company Cell Therapeutics Inc (CTI) should earn an entry in the Guinness Book of World Records for utter and...
This site was started as Lymphoma Resource Page(s) in 1994. The site was designed to collect lymphoma...
Three papers appearing in the journal Blood and pointing towards a regulator-suppressor pill could offer hope to blood cancer...
The US Food and Drug Administration (FDA) has granted a third so-called Breakthrough Therapy Designation for the investigational oral...
The US Food and Drug Administration today has approved an expanded use of Imbruvica (ibrutinib) in patients with...
The U.S. Food and Drug Administration has announced that it has granted "Breakthrough Therapy Designation" for the investigational agent...
According to a new study published in the Proceedings of the National Academy of Sciences, a team from the University of California, San...
Pharmacyclics has announced that the company has submitted a New Drug Application (NDA) to the US Food and Drug Administration (FDA) for...
New research suggests that frontline radioimmunotherapy...
Gilead Sciences has announced results of the company's Phase II study of its investigational compound idelalisib, an oral inhibitor of...